Compare Natera Inc. Common Stock (NTRA) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Tesla, Inc. — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Tesla, Inc. trades at $361.32 (market cap $1.45T). The key difference: Tesla, Inc. is far larger — about 25.4× Natera Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Tesla, Inc. for 88 Days on average.
| NTRA | TSLA | |
|---|---|---|
Market Cap | $57.03B | $1.45T |
Volume | 1,131,157 | 30,868,569 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $489.88 |
52-Week Low | $179.42 | $298.16 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $56.18B | $1.42T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Tesla (TSLA) trades at $375.20, down 0.75% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The stock faces fundamental headwinds with a high P/E ratio of 347.44 and declining profit margins, though it has beaten earnings estimates in two of the last three quarters. Recent news highlights regulatory approval for its driver-assistance software in Europe and a strategic pivot toward robotics and AI.
The outlook remains bifurcated: long-term growth potential in autonomy and energy storage offers upside, but near-term risks include intense EV competition, earnings volatility, and rich valuations. Analyst consensus is a Buy with a $441.36 price target, yet investor sentiment is cautious due to delivery misses and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
